Clinical Trials | December 04, 2025
Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Subscribe To Our Newsletter & Stay Updated
